一名在辅助使用卡立普多后患有难治性抑郁症的“唤醒者”患者。
An "Awakener" Patient Suffering From Treatment-Resistant Depression Following Adjunctive Cariprazine.
作者信息
Bonotis Konstantinos
机构信息
Department of Psychiatry, University of Thessaly, Larissa, GRC.
出版信息
Cureus. 2024 Jan 30;16(1):e53246. doi: 10.7759/cureus.53246. eCollection 2024 Jan.
Abstract
This report presents a case of particular interest in terms of course and therapeutic outcomes, concerning a patient suffering from treatment-resistant depression in whom adjunctive cariprazine to medication brought about an immediate overall improvement in symptomatology. Informed written consent was obtained from the subject for publication of the case.
摘要
本报告介绍了一例在病程和治疗结果方面特别引人关注的病例，该患者患有难治性抑郁症，在药物治疗中加用卡立普嗪后症状立即得到全面改善。已获得该受试者的书面知情同意以发表此病例。
相似文献
1
An "Awakener" Patient Suffering From Treatment-Resistant Depression Following Adjunctive Cariprazine.一名在辅助使用卡立普多后患有难治性抑郁症的“唤醒者”患者。
Cureus. 2024 Jan 30;16(1):e53246. doi: 10.7759/cureus.53246. eCollection 2024 Jan.
2
Cariprazine Add-on in Inadequate Clozapine Response: A Report on Two Cases.卡立普嗪辅助治疗氯氮平反应欠佳：两例报告
Clin Psychopharmacol Neurosci. 2021 Feb 28;19(1):174-178. doi: 10.9758/cpn.2021.19.1.174.
3
Cariprazine on Psychosis: Beyond Schizophrenia - A Case Series.卡立普嗪治疗精神病：超越精神分裂症——病例系列
Neuropsychiatr Dis Treat. 2022 Jul 5;18:1351-1362. doi: 10.2147/NDT.S355941. eCollection 2022.
4
Case Report: Long-Acting Oral Cariprazine.病例报告：长效口服卡立普嗪
Front Psychiatry. 2022 Apr 27;13:876003. doi: 10.3389/fpsyt.2022.876003. eCollection 2022.
5
Cariprazine Augmentation to Antidepressant Therapy in Major Depressive Disorder: Results of a Randomized, Double-Blind, Placebo-Controlled Trial.卡立普嗪辅助治疗重度抑郁症：一项随机、双盲、安慰剂对照试验的结果
Psychopharmacol Bull. 2018 Jun 20;48(4):62-80.
6
Cariprazine for the Treatment of Schizophrenia: A Review of this Dopamine D3-Preferring D3/D2 Receptor Partial Agonist.卡立普嗪用于治疗精神分裂症：对这种优先作用于多巴胺D3的D3/D2受体部分激动剂的综述
Clin Schizophr Relat Psychoses. 2016 Summer;10(2):109-19. doi: 10.3371/1935-1232-10.2.109.
7
Medication-Induced Akathisia with Newly Approved Antipsychotics in Patients with a Severe Mental Illness: A Systematic Review and Meta-Analysis.新型抗精神病药物致严重精神障碍患者药物性静坐不能的系统评价和 Meta 分析。
CNS Drugs. 2019 Jun;33(6):549-566. doi: 10.1007/s40263-019-00625-3.
8
Add-on Cariprazine in Patients with Long-term Clozapine Treatment and Treatment Resistant Schizophrenia: Two Cases of Psychotic Deterioration and Pisa Syndrome.长期使用氯氮平治疗且难治性精神分裂症患者加用卡立普嗪：两例精神病性恶化和匹萨综合征病例
Clin Psychopharmacol Neurosci. 2022 May 31;20(2):398-401. doi: 10.9758/cpn.2022.20.2.398.
9
Switching Clozapine to Cariprazine in Three Patients with Persistent Symptoms of Schizophrenia: A Case Series.三名持续性精神分裂症症状患者从氯氮平换用卡立普唑：病例系列
Neuropsychiatr Dis Treat. 2022 Jul 13;18:1433-1440. doi: 10.2147/NDT.S367922. eCollection 2022.
10
Case Report: Cariprazine Efficacy in Young Patients Diagnosed With Schizophrenia With Predominantly Negative Symptoms.病例报告：卡立哌嗪对以阴性症状为主的青少年精神分裂症患者的疗效
Front Psychiatry. 2021 Nov 22;12:786171. doi: 10.3389/fpsyt.2021.786171. eCollection 2021.
本文引用的文献
1
A New Option for Depressed Patients Who Do Not Respond to Antidepressant Medications.对抗抑郁药物无反应的抑郁症患者的一种新选择。
Am J Psychiatry. 2023 Mar 1;180(3):188-189. doi: 10.1176/appi.ajp.20230039.
2
Insights and Advances Into Treatments for Major Depression.重度抑郁症治疗的见解与进展
Am J Psychiatry. 2023 Mar 1;180(3):173-176. doi: 10.1176/appi.ajp.20230041.
3
Pharmacotherapies for Treatment-Resistant Depression: How Antipsychotics Fit in the Rapidly Evolving Therapeutic Landscape.难治性抑郁症的药物治疗：抗精神病药物在快速演变的治疗格局中的作用。
Am J Psychiatry. 2023 Mar 1;180(3):190-199. doi: 10.1176/appi.ajp.20230025.
4
Alcohol and the Etiology of Depression.酒精与抑郁症的病因
Am J Psychiatry. 2023 Mar 1;180(3):179-181. doi: 10.1176/appi.ajp.20230004.
5
Adjunctive Cariprazine for the Treatment of Patients With Major Depressive Disorder: A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study.阿立哌唑辅助治疗重度抑郁症患者：一项随机、双盲、安慰剂对照的3期研究。
Am J Psychiatry. 2023 Mar 1;180(3):241-251. doi: 10.1176/appi.ajp.20220504. Epub 2023 Feb 15.
6
Seventy Years of Antipsychotic Development: A Critical Review.抗精神病药物研发七十年：批判性综述
Biomedicines. 2023 Jan 4;11(1):130. doi: 10.3390/biomedicines11010130.
7
New Atypical Antipsychotics in the Treatment of Schizophrenia and Depression.新型非典型抗精神病药物在精神分裂症和抑郁症治疗中的应用。
Int J Mol Sci. 2022 Sep 13;23(18):10624. doi: 10.3390/ijms231810624.
8
Evaluation of cariprazine in the treatment of bipolar I and II depression: a randomized, double-blind, placebo-controlled, phase 2 trial.卡利拉嗪治疗双相 I 型和 II 型抑郁症的疗效评价：一项随机、双盲、安慰剂对照、2 期临床试验。
Int Clin Psychopharmacol. 2020 May;35(3):147-156. doi: 10.1097/YIC.0000000000000307.
9
Cariprazine Augmentation to Antidepressant Therapy in Major Depressive Disorder: Results of a Randomized, Double-Blind, Placebo-Controlled Trial.卡立普嗪辅助治疗重度抑郁症：一项随机、双盲、安慰剂对照试验的结果
Psychopharmacol Bull. 2018 Jun 20;48(4):62-80.
10
Long-term safety and tolerability of cariprazine as adjunctive therapy in major depressive disorder.卡利拉嗪作为辅助治疗重度抑郁症的长期安全性和耐受性。
Int Clin Psychopharmacol. 2019 Mar;34(2):76-83. doi: 10.1097/YIC.0000000000000246.
Zotero 插件